Top Markets
Coin of the day
Sigilon Therapeutics, Inc. Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc.

SGTX
주식 순위 #25416
Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015,... Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.
주가
$22.47
마지막 동기화: 2023-08-18
시가총액
$49.76M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Sigilon Therapeutics, Inc. (SGTX)

카테고리

Sigilon Therapeutics, Inc. (SGTX)의 주가 이력
최고 종가: $22.30 (2023-08-01 기준)

최저 종가: $453.71 (2020-12-01 기준)
Sigilon Therapeutics, Inc.의 주가 이력 (2020 ~ 2026)
연간 주가 성과
연도 성과
2023 400.06%
2022 -87.99%
2021 -91.82%
2020 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$539.14 35.65%
US
$1.04K 56.21%
NL
$117.80 -18.86%
AU
$761.87 8.65%
CH
$130.43 397.46%
US